Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

Amgen (AMGN) closed the most recent trading day at $280.35, moving +1.03% from the previous trading session. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...